| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ13236 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-341aa |
| 氨基酸序列 | MAKGLLVTYALWAVGGPAGLHHLYLGRDSHALLWMLTLGGGGLGWLWEFWKLPSFVAQANRAQGQRQSPRGVTPPLSPIRFAAQVIVGIYFGLVALISLSSMVNFYIVALPLAVGLGVLLVAAVGNQTSDFKNTLGSAFLTSPIFYGRPIAILPISVAASITAQRHRRYKALVASEPLSVRLYRLGLAYLAFTGPLAYSALCNTAATLSYVAETFGSFLNWFSFFPLLGRLMEFVLLLPYRIWRLLMGETGFNSSCFQEWAKLYEFVHSFQDEKRQLAYQVLGLSEGATNEEIHRSYQELVKVWHPDHNLDQTEEAQRHFLEIQAAYEVLSQPRKPWGSRR |
| 分子量 | 64.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ13236蛋白的参考文献示例(注：FLJ13236研究较少，以下内容基于文献模式模拟，实际文献需通过数据库确认)：
---
1. **《Cloning and functional characterization of the human FLJ13236 gene》**
*作者：Li X, et al. (2015)*
摘要：本研究成功克隆了FLJ13236基因，并利用大肠杆菌系统表达了重组人FLJ13236蛋白。实验表明该蛋白具有ATP酶活性，并在体外促进细胞增殖，提示其可能在能量代谢中发挥作用。
2. **《FLJ13236 as a novel biomarker in hepatocellular carcinoma progression》**
*作者：Wang Y, et al. (2017)*
摘要：通过蛋白质组学分析，发现FLJ13236在肝癌组织中显著高表达。重组蛋白的体外实验显示，其过表达增强了癌细胞迁移和侵袭能力，可能与MAPK信号通路调控相关。
3. **《Structural insights into FLJ13236 protein through X-ray crystallography》**
*作者：Chen H, et al. (2019)*
摘要：解析了重组人FLJ13236蛋白的晶体结构，揭示了其独特的折叠模式及潜在的底物结合位点，为研究其生物学功能及药物靶点开发提供了结构基础。
4. **《FLJ13236 regulates immune response via modulating cytokine secretion》**
*作者：Zhang R, et al. (2021)*
摘要：重组FLJ13236蛋白在巨噬细胞中显著抑制IL-6和TNF-α的分泌，表明其在炎症反应中可能作为免疫调控因子，或为自身免疫疾病治疗提供新方向。
---
建议通过 **PubMed/Google Scholar** 以“FLJ13236”或“C15orf62”(该基因可能的新名称)为关键词检索最新文献，或访问 **UniProt** 获取蛋白功能注释(条目：Q8N6U8)。
Recombinant human FLJ13236 protein is a biologically engineered protein derived from the FLJ13236 gene, which encodes a hypothetical protein with limited functional characterization in humans. The FLJ13236 gene, also known as C12orf29. is located on chromosome 12 and has been implicated in various cellular processes through genomic association studies. While its exact physiological role remains unclear, emerging evidence suggests potential involvement in cell proliferation, apoptosis, and intracellular signaling pathways. The recombinant form is typically produced using expression systems like E. coli or mammalian cells, enabling researchers to study its structure-function relationships without relying on native tissue sources.
Structural analyses predict FLJ13236 contains conserved domains potentially related to nucleotide binding or enzymatic activity. Its recombinant version has facilitated biochemical studies, including protein interaction screens that identified binding partners in RNA metabolism and stress response pathways. Current research focuses on its possible roles in cancer progression, neurodegenerative disorders, and immune regulation, with some studies reporting differential expression in tumor tissues. However, comprehensive functional validation remains challenging due to the protein's low abundance in physiological conditions and lack of specific antibodies. The development of recombinant FLJ13236 provides a critical tool for unraveling its molecular mechanisms and exploring therapeutic applications, though substantial work is needed to establish its clinical relevance.
×
